Table 3 Clinical features, management and outcomes of surgically induced scleritis following PPV or SB.
Scleritis following pars plana vitrectomy (n = 23 patients (23 eyes)) | Scleritis following scleral buckle (n = 16 patients (17 eyes)) | |
|---|---|---|
Time interval between surgery and scleritis, weeks | 3.6 (2.1–51.7) | 33.4 (5.7–756.7) |
Scleritis subtypes | ||
Anterior diffuse | 16 (70%) | 8 (47%) |
Anterior nodular | 1a (4.3%) | 0 (0%) |
Anterior necrotising | 6 (26%) | 8 (47%) |
Posterior | 2 (8.7%) | 1 (6%) |
Aetiology | ||
Non-infective scleritis | 21 (91%) | 15 (94%) |
Infective scleritis | 2 (8.7%) | 1 (6%) |
Treatment | ||
NSAIDs | 20 (87%) | 11 (65%) |
Systemic steroids | 2 (8.7%) | 5 (17%) |
Immunomodulatory therapy | 1 (4.3%) | 2 (12%) |
Surgical intervention | 2 (8.7%) | 10 (59%) |
Duration of follow-up, months | 15 (5–69) | 8 (5–21) |
Best corrected visual acuity (BCVA), logMAR | ||
At presentation | 0.69 (0.30–1.35) | 0.54 (0.08–1.36) |
At final follow-up | 0.54 (0.08–1.61) | 0.48 (0.10–1.00) |
Change in visionb | −0.18 (−0.40–0.13) | 0.00 (−0.20–0.08) |
Scleritis recurrence | 4 (17%) | 5 (29%) |
